Christina Korownyk, Scott Garrison, Michael R. Kolber
Abstract
Do the neuraminidase inhibitors (NIs) oseltamivir or zanamivir improve clinical outcomes in influenza? Biased, poor-quality, mostly unpublished evidence suggests that oseltamivir and zanamivir shorten the duration of influenza symptoms by 0.6 to 0.7 of a day. Pneumonia and hospitalizations are not
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Do the neuraminidase inhibitors (NIs) oseltamivir or zanamivir improve clinical outcomes in influenza? Biased, poor-quality, mostly unpublished evidence suggests that oseltamivir and zanamivir shorten the duration of influenza symptoms by 0.6 to 0.7 of a day. Pneumonia and hospitalizations are not
Key concepts: Zanamivir, Oseltamivir, Neuraminidase, Medicine, Pneumonia, Neuraminidase inhibitor, Virology, Intensive care medicine